-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Two autologous anti-CD19 chimeric antigen receptor (CAR) T cells (axicabtagene ciloleucel[axi-cel] and tisagenlecleucel[tisa-cel]) have been approved for marketing in Europe for the treatment of relapsed/refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).
Lymphoma
The researchers retrospectively collected data on 70 patients who received commercial CAR T cells at their institution from January 2018 to November 2019.
The results of multivariate analysis showed that the factors associated with poor PFS were the number of treatment lines (≥4) of CAR T cells (P = .
immunity
In summary, this analysis describes a study cohort of patients with R/R aggressive B-cell lymphoma using axi-cel and tisa-cel in the real world in Europe.
Original source:
Hideki Goto, Shinichi Makita, et al.
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed / refractory diffuse large B-cell lymphoma in this message